Category : Healthcare and Pharmaceuticals | Published at : November-2020 | Delivery Format : PDF | Status: Published | Pages : 190
The market for Seasonal Affective Disorder is expected to grow at a CAGR of around 3.5% from 2020 to 2027 and expected to reach the market value of around US$ 667.5 Mn by 2027.
Seasonal Affective Disorder (SAD) refers to a type of depression associated with the changes in seasons. It begins and ends at about the same time every year. The treatment of SAD may include light therapy, medications, and psychotherapy. The most likely signs and symptoms of SAD may include feeling depressed most of the day, having low energy, losing interest in activities once enjoyed, feeling sluggish or agitated, having problems with sleeping, experiencing changes in appetite or weight, having difficulty concentrating, feeling hopeless, worthless or guilty, and having frequent thoughts of death or suicide. The disorder is commonly found in women and between 15 to 55 years of age.
Market Dynamics
The growing awareness regarding mental health, especially depression across the globe is supporting the regional market growth. The changing lifestyle along with rapid urbanization and hectic work-life schedules are bolstering the market growth. The increasing number of physician visits related to seasonal affective disorder in developed and developing economies is further bolstering market growth. The availability and adoption of new treatments for this disorder owing to the ongoing research and development efforts made by the major players are supporting the market growth. Additionally, rapid technological advancement and ongoing R&D activities in emerging economies are projected to create potential opportunities over the forecast period from 2020 to 2027.
On the other hand, low prevalence rate, less awareness of this disorder, and limited access to the healthcare facilities in some untapped economies are projected to limit the growth to an extent over the forecast period.
Segment Instance
North America accounted for the maximum share in the Seasonal Affective Disorder market
In 2019, North America is leading the market with maximum revenue share (%) in the seasonal affective disorder market. The well-established healthcare infrastructure of the developed economies including the US and Canada is supporting the regional market value. The ongoing efforts made by the major authorities to spread awareness and appropriate ways to deal with the early symptoms are boosting the regional market growth. Moreover, SAD is estimated to affect 10 million Americans and another 10% to 20% may have the mild seasonal affective disorder (SAD). Additionally, according to some estimates in Washington, seasonal affective disorder (SAD) has begun to collide with Covid-19 pandemic fatigue and other mental health issues exacerbated by the social isolation of lockdown, which has been exacerbated by the failed political response to the coronavirus pandemic. The increasing number is the result of mounting psychological distress due to rising unemployment and direct or indirect loss of belongings.
Moreover, Asia Pacific is likely to experience the fastest growth throughout the forecast timeframe from 2020 to 2027. The developing healthcare sector and rapid urbanization are supporting regional market growth. The increasing hectic and busy work-life culture in the fast pace market condition, rising competition among people in terms of money, and positions are other factors supporting the market growth. The rapidly developing economies including China and India are the major contributors to the regional market growth.
Key Market Players
The players profiled in the report include AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein Inc. (US), Pfizer Inc. (US), and others. The major market players were involved in mergers and acquisitions, partnerships & collaborations, and new source development for the expansion of market share (%).
Market Segmentation
Market By Type
Fall and winter SAD
Spring and summer SAD
Others
Market By Treatment
Light Therapy (Phototherapy)
Medications
Others
Market By End User
Hospital
Clinic
Household
Other
Market By Geography
North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The market for seasonal affective disorder is expected to reach a market value of around US$ 667.5 Mn by 2027
The seasonal affective disorder market is expected to grow at a CAGR of around 3.5% from 2020 to 2027
The growing awareness regarding mental health, especially depression, changing lifestyle along with rapid urbanization and hectic work life schedules, increasing number of physician visits related to seasonal affective disorder, availability and adoption of new treatments for this disorder, and ongoing research and development efforts made by the major players are some of the major factors bolstering the market growth.
AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein Inc. (US), Pfizer Inc. (US), and others are the prominent players in the market.
North America held the highest market share in the seasonal affective disorder market
Asia pacific is expected to be the fastest growing market over the forecast period
In Treatment segment the Light Therapy (Phototherapy) segment is growing at faster pace.
